Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €1.10 EUR
Change Today -0.04 / -3.51%
Volume 245.2K
As of 11:35 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

neovacs (ALNEV) Snapshot

Open
€1.14
Previous Close
€1.14
Day High
€1.14
Day Low
€1.10
52 Week High
09/16/14 - €4.04
52 Week Low
03/27/15 - €0.93
Market Cap
26.1M
Average Volume 10 Days
425.8K
EPS TTM
€-0.33
Shares Outstanding
23.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOVACS (ALNEV)

Related News

No related news articles were found.

neovacs (ALNEV) Related Businessweek News

No Related Businessweek News Found

neovacs (ALNEV) Details

Neovacs S.A., a biotechnology company, focuses on active immunotherapy for autoimmune and inflammatory diseases in France. The company’s product pipeline comprises tumor necrosis factor kinoid for the treatment of rheumatoid arthritis and Crohn’s diseases; interferon a-kinoid to treat lupus; and vascular endothelial growth factor kinoid for the treatment of macular degeneration and cancer. Neovacs S.A. is based in Paris, France.

17 Employees
Last Reported Date: 03/23/15

neovacs (ALNEV) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: €34.9K
Compensation as of Fiscal Year 2013.

neovacs (ALNEV) Key Developments

Neovacs Announces Formation of Clinical Advisory Board

Neovacs has formed a cross disciplinary Clinical Advisory Board (CAB) composed of leading experts in Dermatomyositis (DM). Prof. Olivier Benveniste, M.D., Ph.D., Hôpital Pitié-Salpêtrière, Paris; Prof. Eric Hachulla, M.D., Ph.D., Centre Hospitalier Regional Universitaire de Lille, France; Dr. Jean-David Bouaziz, M.D.,Ph.D., Hospital Saint-Louis, Paris; Prof. Werner Stenzel, M.D.,Ph.D., Charité Universitätmedizin Berlin; and Prof. Ingrid Lundberg, M.D., Karolinska Universitetssjukhuset, Stockholm. These board members will be instrumental not only in bringing their expertise to Neovacs in preparing for and defining the metholodology, target population, and evaluation criteriafor the DM trial; but also in assisting with trial development and patient recruitment.

Neovacs Initiates Clinical Program in Dermatomyositis

NEOVACS announced the launch of its clinical development program in Dermatomyositis (DM), an orphan skin and muscular condition with significant unmet medical need. Neovacs is extending its IFN?-Kinoid clinical program beyond lupus to include adult and pediatric DM - an indication where a positive IFN? signature plays a decisive role1. The decision follows a recommendation earlier this year by the Company's Scientific Advisory Board to pursue IFN?-Kinoid as a potential treatment for DM and extensive due diligence in researching IFN-related diseases that could benefit from this treatment modality. Neovacs plans to conduct a multicentric phase I/IIa trial of IFN?-Kinoid in adult DM in 15 patients which is anticipated to launch in early 2016 in France and other European countries.

Neovacs S.A. Presents at French Life Science Days conference, Jun-17-2015

Neovacs S.A. Presents at French Life Science Days conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNEV:FP €1.10 EUR -0.04

ALNEV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALNEV.
View Industry Companies
 

Industry Analysis

ALNEV

Industry Average

Valuation ALNEV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 163.3x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 120.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOVACS, please visit www.neovacs.fr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.